FUJIFILM Biotechnologies

Articles

The management of lung cancer brain metastases has seen significant advancements, with a focus on personalized treatment strategies. The integration of targeted therapies and immunotherapies has improved patient outcomes, offering more effective and less invasive options compared to traditional methods. Stereotactic radiosurgery and whole-brain radiation therapy remain crucial, but their roles are evolving with the advent of novel systemic treatments. Multidisciplinary approaches are essential for optimizing care, emphasizing the importance of collaboration among oncologists, neurosurgeons, and radiation specialists to tailor interventions based on individual patient profiles.

This white paper offers concise, practical guidance for biopharma teams outsourcing Process Characterization (PC) to strengthen CMC packages and accelerate commercialization. 

Practical Considerations for Your Sub-contracted Process Characterization Study

Microbial cell culture processes are diverse and difficult to harmonize, however, with a new microbial purification platform, downstream processes are streamlined. Applicable for use in E. coli and P. pastoris, this microbial purification platform utilizes a novel scarless protease to reduce purification steps, accelerating the journey from PD to GMP.

Precision Purification Technology for Complex Biologics

Discover how a “Predict-First” approach uses AI-driven in silico models to de-risk mAb development. See real-case results and a manufacturability scoring framework that accelerates decisions and speeds therapies to market.



Predict First Approach - How In Silico Strategies Can Enhance Efficiency in Monoclonal Antibody Bioprocess Development

Discover proven strategies and innovative technologies to streamline microbial development, from early studies to GMP readiness. Learn from industry experts how to boost productivity, overcome bottlenecks, and move therapies to patients faster.

https://www.biopharminternational.com/bp_w/gene_to_gmp

In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to good manufacturing process (GMP) with greater speed and efficiency. This webinar will highlight strategies to streamline development timelines, with a focus on adopting innovative approaches and technologies. You’ll hear how leading experts are optimizing microbial fermentation, scaling production while meeting regulatory requirements, and preparing for smoother transitions from early studies to GMP readiness. Join us to discover how smarter, faster process development can help you bring therapies to patients more effectively.



Proven strategies to overcome common challenges and bottlenecks

Techniques to boost productivity and shorten time to market

Practical solutions for advancing microbial processes efficiently

Methods to enable quicker transitions to toxicology trials and GMP manufacturing

Perspectives on the future of expedited microbial downstream processing

Large and small biotech companies and spin outs


Director, Commercial Technical Lead for Biologics
FUJIFILM Biotechnologies


, PhD, serves as director, commercial technical lead for biologics at FUJIFILM Biotechnologies. With over 19 years in the biotechnology industry, he excels in strategic growth and project management, focusing on mammalian cell culture and microbial service offerings. Loftus plays a pivotal role in solution-based selling, aligning technical offerings with client needs, and guiding FUJIFILM Biotechnologies to industry leadership. Loftus holds a PhD in biochemistry/biophysics from the University of York and a degree in medical microbiology from the University of Newcastle.

Webcasts

Webinar Date/Time: Tue, Feb 24, 2026 11:00 AM EST

Shaping the Future of Microbial Development: From Gene to GMP

I'm sorry, but it seems that there is no article text provided for me to summarize and analyze. Please provide the text of the article, and I will be happy to assist you with a summary and key takeaways

Case study showcasing accelerated PPQ for an E. coli–expressed orphan therapy, achieving three PPQ batches in 18 months through high-compliance manufacturing. 

Lab to Launch Faster

The management of lung cancer brain metastases has seen significant advancements, with a focus on personalized treatment strategies. The integration of targeted therapies and immunotherapies has improved patient outcomes, offering more effective and less invasive options compared to traditional methods. Stereotactic radiosurgery and whole-brain radiation therapy remain crucial, but their roles are evolving with the advent of novel systemic therapies. Multidisciplinary approaches are essential for optimizing treatment plans, considering factors such as genetic mutations, patient performance status, and potential side effects. Ongoing research continues to refine these strategies, aiming for improved survival and quality of life.

Discover how a robust platform enables fast, high-quality bispecific antibody production by optimizing gene ratios, CLD, and analytics for purity and yield.